← Back to Search

RNA Vaccine

PF-07836395 Influenza saRNA for Flu

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1-, 2-, and 4-weeks after vaccination
Awards & highlights

Study Summary

This trial is to see if a new vaccine for the flu is safe and effective.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1-, 2-, and 4-weeks after vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1-, 2-, and 4-weeks after vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of participants reporting adverse events
Percentage of participants reporting local reactions
Percentage of participants reporting serious adverse events
+5 more
Secondary outcome measures
Geometric mean fold rise (GMFR) in HAI titers from before vaccination to each subsequent timepoint
Geometric mean titers (GMTs) of hemagglutination inhibition (HAI) titers
Proportion of participants achieving HAI seroconversion for each strain
+1 more

Trial Design

26Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: PF-07915048 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group II: PF-07914705 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group III: PF-07914705 Influenza saRNA mid doseExperimental Treatment1 Intervention
Group IV: PF-07871987 Influenza saRNA, mid doseExperimental Treatment1 Intervention
Group V: PF-07871987 Influenza saRNA, low doseExperimental Treatment1 Intervention
Group VI: PF-07871987 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group VII: PF-07867246 Influenza saRNA, mid doseExperimental Treatment1 Intervention
Group VIII: PF-07867246 Influenza saRNA, low doseExperimental Treatment1 Intervention
Group IX: PF-07867246 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group X: PF-07852352 Influenza saRNA, mid doseExperimental Treatment1 Intervention
Group XI: PF-07852352 Influenza saRNA, low doseExperimental Treatment1 Intervention
Group XII: PF-07852352 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group XIII: PF-07836396 Influenza saRNA, mid doseExperimental Treatment1 Intervention
Group XIV: PF-07836396 Influenza saRNA, low doseExperimental Treatment1 Intervention
Group XV: PF-07836396 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group XVI: PF-07836395 Influenza saRNA, mid doseExperimental Treatment1 Intervention
Group XVII: PF-07836395 Influenza saRNA, low doseExperimental Treatment1 Intervention
Group XVIII: PF-07836395 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group XIX: PF-07836394 Influenza saRNA, mid doseExperimental Treatment1 Intervention
Group XX: PF-07836394 Influenza saRNA, low doseExperimental Treatment1 Intervention
Group XXI: PF-07836394 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group XXII: PF-07836391 Influenza saRNA, mid doseExperimental Treatment1 Intervention
Group XXIII: PF-07836391 Influenza saRNA, low doseExperimental Treatment1 Intervention
Group XXIV: PF-07836391 Influenza saRNA, high doseExperimental Treatment1 Intervention
Group XXV: Quadrivalent influenza vaccine (QIV)Active Control1 Intervention
Group XXVI: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07867246 Influenza saRNA
2022
Completed Phase 1
~450
PF-07915048 Influenza saRNA
2022
Completed Phase 1
~450
PF-07871987 Influenza saRNA
2022
Completed Phase 1
~450
PF-07914705 Influenza saRNA
2022
Completed Phase 1
~450
PF-07852352 Influenza saRNA 1
2022
Completed Phase 1
~450
PF-07836391 Influenza saRNA
2022
Completed Phase 1
~450
PF-07836394 Influenza saRNA
2022
Completed Phase 1
~450
PF-07836395 Influenza saRNA
2022
Completed Phase 1
~450
PF-07836396 Influenza saRNA
2022
Completed Phase 1
~450

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,581 Previous Clinical Trials
14,633,786 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,486 Previous Clinical Trials
11,810,661 Total Patients Enrolled
~143 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top